Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17197635 | 0.89 | HSP90AB1 (0.41) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL6833575 | 0.88 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3850987 | 0.86 | HDAC6 (0.45) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL13714798 | 0.85 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL13714819 | 0.85 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL17194164 | 0.83 | HPRT1 (0.52) | — | |
| SCHEMBL2606971 | 0.83 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3850990 | 0.80 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL13714840 | 0.79 | HSP90AB1 (0.35) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL13715024 | 0.79 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2017-08-17 | — | — | US | disclosed |
| US-9593137-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HSP90AB1 1459/4885HSP90AA1 1251/4885HDAC6 3064/4885 |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | HSP90AB1 1459/4885HSP90AA1 1251/4885HDAC6 3064/4885 |
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | HSP90AB1 2085/4885HSP90AA1 3445/4885HDAC6 4475/4885 |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | TERT, POT1, TERF2 | HSP90AB1 1500/4885HSP90AA1 1255/4885HDAC6 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.